Baricitinib and ritlecitinib in alopecia areata: A nationwide prospective real-world registry study
JAAD International · 2026-12 · 29 · 105-114
DOI: 10.1016/j.jdin.2026.09.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAAD International, 2026-12. Verfasst von Mathias Willaert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer BV, Eli Lilly.
Abstract (Originalsprache)
Background
Janus kinase inhibitors baricitinib and ritlecitinib are approved for the treatment of severe alopecia areata (AA). However, prospective real-world data on effectiveness, disease burden, and tolerability are limited.
Objective
To evaluate the real-world effectiveness and tolerability of baricitinib and ritlecitinib in adults with AA.
Methods
In this nationwide, prospective, multicenter registry (Systemic Treatments for Alopecia Areata Registry), adults initiating baricitinib or ritlecitinib between January 2024 and April 2026 were included. The primary outcome was Severity of Alopecia Tool (SALT) score trajectory over 12 months, analyzed using a linear mixed model adjusted for baseline SALT score, AA subtype, age, sex, atopic history, disease duration, prior treatment response, and prior Janus kinase inhibitor use.
Results
A total of 166 patients were included (baricitinib, n = 106; ritlecitinib, n = 60). SALT scores declined significantly over time in both groups (β = -4.22 points/mo), with no significant difference between treatments. At 12 months, adjusted SALT scores were 33.7 for baricitinib and 33.4 for ritlecitinib, with SALT ≤20 achieved by 30 of 47(64%) and 12 of 24(50%) of patients, respectively. Both treatments were associated with improvements in disease burden and were well tolerated.
Limitations
Nonrandomized design with potential confounding by indication; decreasing sample sizes at later time points reflecting ongoing registry accrual.
Conclusions
Baricitinib and ritlecitinib demonstrated similar scalp hair regrowth in this prospective real-world cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands.
- Department of Dermatology, Spaarne Gasthuis, Haarlem, The Netherlands.
- Department of Dermatology, Intermedica Kliniek, Wijchen, The Netherlands.
- Department of Dermatology, Bernhoven Hospital, Uden, The Netherlands.
- Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Förderung
- Pfizer BV
- Eli Lilly
Zitieren
APA
Willaert, M., van Helmond, S. C., van Vugt, L., Gostyński, A., van Dongen, T. H., Janmohamed, S. R., Zweers, M., Nijsten, T. E. C., Hijnen, D., & Waalboer-Spuij, R. (2026). Baricitinib and ritlecitinib in alopecia areata: A nationwide prospective real-world registry study. JAAD International, 29, 105-114. https://doi.org/10.1016/j.jdin.2026.09.010
Vancouver
Willaert M, van Helmond SC, van Vugt L, Gostyński A, van Dongen TH, Janmohamed SR, et al. Baricitinib and ritlecitinib in alopecia areata: A nationwide prospective real-world registry study. JAAD International. 2026;29:105-114. doi:10.1016/j.jdin.2026.09.010
BibTeX
@article{Willaert2026,
author = {Willaert, Mathias and van Helmond, Sophie C and van Vugt, Lieke and Gostyński, Antoni and van Dongen, Tristan H and Janmohamed, Sherief R and Zweers, Manon and Nijsten, Tamar E C and Hijnen, DirkJan and Waalboer-Spuij, Rick},
title = {Baricitinib and ritlecitinib in alopecia areata: A nationwide prospective real-world registry study},
journal = {JAAD International},
year = {2026},
volume = {29},
pages = {105--114},
doi = {10.1016/j.jdin.2026.09.010}
}
EUVIMED